Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
Colman RJ, Mizuno T, Fukushima K, Haslam DB, Hyams JS, Boyle B, Noe JD, D'Haens GR, Van Limbergen J, Chun K, Yang J, Denson LA, Ollberding NJ, Vinks AA, Minar P. Colman RJ, et al. Among authors: hyams js. Aliment Pharmacol Ther. 2023 Mar;57(5):524-539. doi: 10.1111/apt.17277. Epub 2022 Oct 31. Aliment Pharmacol Ther. 2023. PMID: 36314265 Free PMC article.
Variation in care in pediatric Crohn disease.
Colletti RB, Baldassano RN, Milov DE, Margolis PA, Bousvaros A, Crandall WV, Crissinger KD, D'Amico MA, Day AS, Denson LA, Dubinsky M, Ebach DR, Hoffenberg EJ, Kader HA, Keljo DJ, Leibowitz IH, Mamula P, Pfefferkorn MD, Qureshi MA; Pediatric IBD Network for Research and Improvement. Colletti RB, et al. J Pediatr Gastroenterol Nutr. 2009 Sep;49(3):297-303. doi: 10.1097/MPG.0b013e3181919695. J Pediatr Gastroenterol Nutr. 2009. PMID: 19590456
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS. Rosh JR, et al. Among authors: hyams js. Am J Gastroenterol. 2009 Dec;104(12):3042-9. doi: 10.1038/ajg.2009.493. Epub 2009 Sep 1. Am J Gastroenterol. 2009. PMID: 19724267
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.
Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV Jr, Kappelman MD, Lewis JD, Parkos CA, Sartor RB; Challenges Workgroup. Denson LA, et al. Inflamm Bowel Dis. 2013 Mar-Apr;19(4):677-82. doi: 10.1097/MIB.0b013e31828134b3. Inflamm Bowel Dis. 2013. PMID: 23448796 Free PMC article. No abstract available.
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS; PRO-KIIDS Research Group. Walters TD, et al. Among authors: hyams js. Gastroenterology. 2014 Feb;146(2):383-91. doi: 10.1053/j.gastro.2013.10.027. Epub 2013 Oct 23. Gastroenterology. 2014. PMID: 24162032
The treatment-naive microbiome in new-onset Crohn's disease.
Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. Gevers D, et al. Cell Host Microbe. 2014 Mar 12;15(3):382-392. doi: 10.1016/j.chom.2014.02.005. Cell Host Microbe. 2014. PMID: 24629344 Free PMC article.
Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.
Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA. Minar P, et al. Among authors: hyams js. Inflamm Bowel Dis. 2014 Jun;20(6):1037-48. doi: 10.1097/MIB.0000000000000049. Inflamm Bowel Dis. 2014. PMID: 24788216 Free PMC article.
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature.
Haberman Y, Tickle TL, Dexheimer PJ, Kim MO, Tang D, Karns R, Baldassano RN, Noe JD, Rosh J, Markowitz J, Heyman MB, Griffiths AM, Crandall WV, Mack DR, Baker SS, Huttenhower C, Keljo DJ, Hyams JS, Kugathasan S, Walters TD, Aronow B, Xavier RJ, Gevers D, Denson LA. Haberman Y, et al. Among authors: hyams js. J Clin Invest. 2014 Aug;124(8):3617-33. doi: 10.1172/JCI75436. Epub 2014 Jul 8. J Clin Invest. 2014. PMID: 25003194 Free PMC article.
Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.
Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, Rick J, Mack D, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Boyle B, Oliva-Hemker M, Keljo D, Pfefferkorn M, Faubion W, Kappelman MD, Sudel B, Markowitz J, Hyams JS. Grossi V, et al. Among authors: hyams js. Clin Gastroenterol Hepatol. 2015 Oct;13(10):1748-56. doi: 10.1016/j.cgh.2015.04.010. Epub 2015 Apr 21. Clin Gastroenterol Hepatol. 2015. PMID: 25911120
336 results